Lupin Limited, a global pharmaceutical business, has announced the U.S. introduction of its Bumetanide Injection USP, which is available in 1 mg/4 mL (0.25 mg/mL) single-dose vials and 2.5 mg/10 mL (0.25 mg/mL) multiple-dose vials. This follows FDA approval.         

Bumetanide Injection USP is a generic version of Bumex Injection (0.25 mg/mL), which is made by Validus Pharmaceuticals LLC. The medicine is prescribed to treat oedema caused by congestive heart failure, hepatic disease, renal illness, or nephrotic syndrome.  

This product's entrance into the US market is important, as Bumetanide Injection USP (RLD Bumex) had a projected annual sales of $20 million in the US in September 2024, according to IQVIA MAT data.  

Lupin's introduction is consistent with its strategic goal of offering inexpensive and accessible treatment alternatives for essential medical problems. This recent deal boosts Lupin's portfolio in the United States, a critical market for the pharmaceutical business.  

The company has yet to provide additional distribution information or prospective expansion plans for the newly announced product.